Novavax Stock News

NEW YORK , Nov. 26, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, ZM, NVAX, PTON, and DOCU. Full story available on Benzinga.com

Black Friday Turns Red On "Terrible News" - Global Markets Crater On "Nu Variant" Panic The Friday after thanksgiving is called black Friday because that''s when retailers finally turn profitable for the year. Not so much for market, however, because this morning it''s red as far as the eye can see. The culprit: the same one we discussed late last night - the emergence of a new coronavirus strain detected in South Africa, known as B.1.1.529, which reportedly carries an "extremely high number" of mutations and is “clearly very different” from previous incarnations, which may drive further waves of disease by evading the body’s defenses according to South African scientists, and soon, Anthony Fauci. British authorities think it is the most significant variant to date and have hurried to impose travel restrictions on southern Africa, as did Japan, the Czech Republic and Italy on Friday. The European Union also said it aimed to halt air travel from the region. "Markets have been quite complacent about the pandemic for a while, partly because economies have been able to withstand the impact of selective lockdown measures.

The stock price of Novavax has seen a solid 18% rise in just five trading sessions, while it is up a large 48% in a month. The recent rise can be attributed to Novavax

Shares of Novavax, Inc. (NASDAQ:NVAX) dropped 5.6% during mid-day trading on Wednesday following insider selling activity. The stock traded as low as $185.98 and last traded at $189.42. Approximately 32,563 shares traded hands during trading, a decline of 99% from the average daily volume of 4,608,702 shares. The stock had previously closed at $200.71. Specifically, []

Equities research analysts forecast that Novavax, Inc. (NASDAQ:NVAX) will report $547.57 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Novavaxs earnings. The highest sales estimate is $1.19 billion and the lowest is $78.57 million. Novavax posted sales of $279.66 million during the same quarter []

NEW YORK, Nov. 25, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the Class Period), of the important January 11, 2022 lead plaintiff deadline .

Shares of Novavax, Inc. (NASDAQ:NVAX) have been assigned an average rating of Buy from the seven analysts that are currently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokerages []

RADNOR, Pa., Nov. 25, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed been filed in the United States District Court for the District of Maryland against Novavax, Inc. (Novavax) (NASDAQ: NVAX). The action charges Novavax with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the companys business, operations, and prospects. As a result of Novavaxs materially misleading statements, Novavax investors have suffered significant losses.

The UK Government already has 60million doses of Novavax. It was shown in trials to cause less side effects compared to those triggered by Pfizer, Moderna or even AstraZeneca''s vaccines.

Some good news on the regulatory front wasn''t enough to make investors happy.

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the Class Period), of the important January 11, 2022 lead plaintiff deadline. SO WHAT: If you purchased Novavax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT:

We are increasingly seeing signs that the pandemic is hardly over. The European Union is battling record case levels. Areas of the US are starting to see some similar dynamics. Hospitals in the developed world are beginning to fill back up with Covid patients. It’s a familiar pattern. This shouldn’t come as a total shock as […] The post Therapeutics Candidates in Focus as Covid Data Heads Back to Front Burner (MRK, OTLC, PFE, JNJ, NVAX, BNTX, AZN, MRNA) appeared first on Wall Street PR .

(RTTNews) - Biotechnology company Novavax, Inc. (NVAX) announced Wednesday its submission to the Singapore Health Sciences Authority (HSA) for interim authorization of its COVID-19 vaccine under the Pandemic Special Access Route (PSAR). Novavax has made the submission for the regulatory evaluation by HSA of NVX-CoV2373, the company''s

Will either of these hopeful vaccine makers continue to thrash the market?

(PR-inside.com) BOSTON, MA / ACCESSWIRE / November 23, 2021 / The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Novavax, Inc. (NASDAQ:NVAX). The case is currently in the lead plaintiff stage. Investors who purchased NVAX securities between March 2, 2021 and October 19, 2021 may contact the Thornton Law Firm''s investor protection team by visiting www.tenlaw.com/cases/Novavax for more information. Investors may also email [email protected] or call 617-531-3917. FOR MORE INFORMATION: www.tenlaw.com/cases/Novavax The case alleges that Novavax and its senior executives made misleading statements to investors and failed to disclose that: (i) Novavax overstated ..